| Literature DB >> 27934941 |
Isao Watanabe1,2, Nagato Kuriyama1,3, Fumitaro Miyatani1,2, Ryota Nomura4, Shuhei Naka4, Kazuhiko Nakano4, Masafumi Ihara5, Komei Iwai1,2, Daisuke Matsui1,2, Etsuko Ozaki1, Teruhide Koyama1, Masaru Nishigaki2, Toshiro Yamamoto2, Aiko Tamura3, Toshiki Mizuno3, Kentaro Akazawa6, Akihiro Takada7, Kazuo Takeda7, Kei Yamada6, Masanori Nakagawa3,8, Tokutaro Tanaka9, Narisato Kanamura2, Robert P Friedland10, Yoshiyuki Watanabe1.
Abstract
Cerebral microbleeds (CMBs) are an important risk factor for stroke and dementia. We have shown that the collagen binding surface Cnm protein expressed on cnm-positive Streptococcus mutans is involved in the development of CMBs. However, whether the collagen binding activity of cnm-positive S. mutans is related to the nature of the CMBs or to cognitive impairment is unclear. Two-hundred seventy nine community residents (70.0 years) were examined for the presence or absence of cnm-positive S. mutans in the saliva by PCR and collagen binding activity, CMBs, and cognitive function were evaluated. Cnm-positive S. mutans was detected more often among subjects with CMBs (p < 0.01) than those without. The risk of CMBs was significantly higher (odds ratio = 14.3) in the group with S. mutans expressing collagen binding activity, as compared to the group without that finding. Deep CMBs were more frequent (67%) and cognitive function was lower among subjects with cnm-positive S. mutans expressing collagen binding activity. This work supports the role of oral health in stroke and dementia and proposes a molecular mechanism for the interaction.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27934941 PMCID: PMC5146923 DOI: 10.1038/srep38561
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Cerebral microbleeds (arrows) using the SWI-MRI-based classification is shown in this figure.
(a) Lobar microbleeds distributed across the temporal lobes. (b) Isolated deep microbleeds in the internal aspect of the right putamen.
Characteristics by gender.
| Variable | Males (n = 189) | Females (n = 90) | Total (n = 279) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Clinical characteristics | |||
| Age (years) ± SD | 70.2 ± 6.1 | 68.6 ± 6.0* | 70.0 ± 6.1 |
| Age (range) | 54–87 | 60–89 | 54–89 |
| BMI (kg/m2) ± SD | 23.1 ± 2.7 | 22.0 ± 3.2** | 22.7 ± 3.0 |
| Hypertension | 104 (55) | 41 (46) | 145 (52) |
| Hyperlipidemia | 111 (59) | 54 (60) | 165 (59) |
| Diabetes mellitus | 30 (16) | 5 (5.6)* | 35 (13) |
| History of stroke | 4 (2.1) | 1 (1.1) | 5 (1.8) |
| History of cardiovascular disease | 10 (5.3) | 4 (4.4) | 14 (5.0) |
| Antiplatelet therapy | 23 (12) | 6 (6.7) | 29 (10) |
| Anticoagulant therapy | 10 (5.3) | 1 (1.1) | 11 (3.9) |
| Drinking | 138 (73) | 43 (48)** | 181 (65) |
| Smoking | 27 (14) | 4 (4.4)* | 31 (11) |
| Education ≤12 yearsa | 92 (49) | 58 (66)** | 150 (55) |
| baPWV (m/s) ± SD | 1758 ± 228.2 | 1691 ± 333.4 | 1736 ± 304.6 |
| hs-CRP ≥ 0.1 mg/dL | 50 (27) | 27 (30) | 77 (28) |
| Dental check-up findings | |||
| Number of remaining teeth ± SD | 22.8 ± 7.7 | 22.5 ± 6.9 | 22.7 ± 7.5 |
| Dental caries+ | 69 (37) | 17 (19)** | 86 (31) |
| CPI ≥ code 3 | 55 (29) | 22 (24) | 77 (28) |
| Laboratory evaluations | |||
| APOE ε4 allele carrierb | 35 (19) | 23 (26) | 58 (21) |
| | 171 (91) | 90 (100)** | 261 (94) |
| | 57 (30) | 34 (38) | 91 (33) |
| Collagen binding activity ≥10% | 45 (24) | 26 (29) | 71 (25) |
| Brain MRI findings | |||
| CMBs | 49 (26) | 24 (27) | 73 (26) |
| PVH ≥ grade 2 | 24 (13) | 11 (12) | 35 (13) |
| DWMH ≥ grade 2 | 51 (27) | 26 (29) | 77 (28) |
| Cognitive functional evaluations | |||
| MMSE (score) ± SD | 28.6 ± 1.9 | 27.9 ± 2.5* | 28.3 ± 2.1 |
| Letter fluency tasks | |||
| “Ta” (score) ± SD | 8.3 ± 3.1 | 8.1 ± 3.9 | 8.2 ± 3.3 |
| “Ka” (score) ± SD | 9.9 ± 3.4 | 9.5 ± 3.3 | 9.8 ± 3.4 |
*T-tests p < 0.05 and Chi-square tests p < 0.05, **T-tests p < 0.01 and Chi-square tests p < 0.01.
aData are missing for education (n = 4). bData are missing for APOE genotype (n = 7).
BMI; Body mass index, CPI; Community Periodontal Index, CMBs; Cerebral microbleeds.
PVH; Periventricular Hyperintensity, DWMH; Deep White Matter Hyperintensity, MMSE; Mini-Mental State Examination.
Comparison of clinical characteristics between the cerebral microbleeds (+) group and (−) group.
| Variable | Cerebral microbleeds | |
|---|---|---|
| − (n = 206) | + (n = 73) | |
| n (%) | n (%) | |
| Clinical characteristics | ||
| Age (years) ± SD | 69.5 ± 5.9 | 70.2 ± 6.5 |
| Age (range) | 59–89 | 54–87 |
| Sex (Male) | 140 (68) | 49 (67) |
| BMI (kg/m2) ± SD | 22.5 ± 2.7 | 23.4 ± 3.6* |
| Hypertension | 102 (50) | 43 (59) |
| Hyperlipidemia | 118 (57) | 47 (64) |
| Diabetes mellitus | 27 (13) | 8 (11) |
| History of stroke | 2 (1.0) | 3 (4.1) |
| History of cardiovascular disease | 8 (3.9) | 6 (8.2) |
| Antiplatelet therapy | 17 (8.3) | 12 (16) |
| Anticoagulant therapy | 7 (3.4) | 4 (5.5) |
| Drinking | 140 (68) | 41 (56) |
| Smoking | 26 (13) | 5 (6.8) |
| Education ≤12 yearsa | 108 (53) | 42 (60) |
| baPWV (m/s) ± SD | 1728 ± 306.9 | 1760 ± 298.9 |
| hs-CRP ≥ 0.1 mg/dL | 55 (27) | 22 (30) |
| Dental check-up findings | ||
| Number of remaining teeth ± SD | 22.9 ± 7.2 | 22.3 ± 8.3 |
| Dental caries+ | 60 (29) | 26 (36) |
| CPI ≥ code 3 | 50 (24) | 27 (37)* |
| Laboratory evaluations | ||
| APOE ε4 allele carrierb | 46 (23) | 12 (17) |
| | 192 (93) | 69 (95) |
| | 37 (18) | 54 (74)** |
| Collagen binding activity ≥10% | 28 (14) | 43 (59)** |
| Brain MRI findings | ||
| Distribution of CMBs | ||
| Deep (%) | — | 44 (60) |
| Lobar (%) | — | 20 (27) |
| Mixed (%) | — | 9 (12) |
| PVH ≥ grade 2 | 24 (12) | 11 (15) |
| DWMH ≥ grade 2 | 50 (24) | 27 (37)* |
| Cognitive functional evaluations | ||
| MMSE (score) ± SD | 28.5 ± 2.2 | 27.9 ± 2.0* |
| Letter fluency tasks | ||
| “Ta” (score) ± SD | 8.5 ± 3.5 | 7.6 ± 2.9* |
| “Ka” (score) ± SD | 10.0 ± 3.5 | 9.2 ± 3.0 |
*T-tests p < 0.05 and Chi-square tests p < 0.05, **T-tests p < 0.01 and Chi-square tests p < 0.01.
aData are missing for education (n = 4). bData are missing for APOE genotype (n = 7).
BMI; Body mass index, CPI; Community Periodontal Index, CMBs; Cerebral microbleeds.
PVH; Periventricular Hyperintensity, DWMH; Deep White Matter Hyperintensity, MMSE; Mini-Mental State Examination.
Crude and adjusted odds ratio for the risk of cerebral microbleeds.
| Variable | Crude | Model 1 | Model 2 | |||
|---|---|---|---|---|---|---|
| OR (95% CI)† | OR (95% CI)† | OR (95% CI)† | ||||
| Age | 1.02 (0.98–1.07) | 0.37 | 1.02 (0.98–1.07) | 0.36 | 1.05 (0.98–1.13) | 0.15 |
| Sex (Male) | 0.96 (0.55–1.70) | 0.90 | 0.93 (0.53–1.66) | 0.81 | 0.90 (0.39–2.06) | 0.80 |
| BMI ≥25 kg/m2 | 1.42 (0.73–2.76) | 0.30 | 1.02 (0.51–1.63) | 0.76 | 1.24 (0.47–3.24) | 0.66 |
| Hypertension | 1.46 (0.73–2.76) | 0.17 | 1.47 (0.86–2.54) | 0.16 | 1.36 (0.62–2.98) | 0.44 |
| Hyperlipidemia | 1.35 (0.78–2.34) | 0.29 | 1.38 (0.79–2.40) | 0.26 | 1.59 (0.74–3.42) | 0.23 |
| diabetes mellitus | 0.82 (0.35–1.89) | 0.63 | 0.84 (0.36–1.96) | 0.68 | 0.81 (0.26–2.56) | 0.72 |
| history of stroke | 2.21 (0.74–6.62) | 0.44 | 2.17 (0.72–6.49) | 0.17 | 1.42 (0.31–6.46) | 0.65 |
| history of cardiovascular disease | 4.37 (0.72–26.7) | 0.11 | 3.97 (0.63–24.9) | 0.14 | 2.94 (0.31–28.2) | 0.35 |
| Drinking | 0.60 (0.35–1.04) | 0.07 | 0.59 (0.34–1.05) | 0.73 | 0.65 (0.30–1.38) | 0.26 |
| Smoking | 0.51 (0.19–1.38) | 0.18 | 0.54 (0.19–1.48) | 0.23 | 1.07 (0.31–3.68) | 0.92 |
| antiplatelet therapy | 2.19 (0.99–4.84) | 0.53 | 2.12 (0.94–4.76) | 0.07 | 2.16 (0.64–7.25) | 0.21 |
| anticoagulant therapy | 1.65 (0.47–5.80) | 0.44 | 1.63 (0.46–5.80) | 0.45 | 2.77 (0.57–13.6) | 0.21 |
| Education ≤12 years | 1.35 (0.78–2.34) | 0.29 | 1.32 (0.75–2.31) | 0.34 | 0.70 (0.33–1.47) | 0.35 |
| baPWV (m/s) ± SD | 1.00 (0.99–1.00) | 0.44 | 1.00 (0.99–1.00) | 0.65 | 1.00 (0.99–1.00) | 0.54 |
| hs-CRP ≥0.1 mg/dL | 1.18 (0.66–2.13) | 0.57 | 1.15 (0.64–2.08) | 0.64 | 0.72 (0.32–1.61) | 0.43 |
| Dental caries+ | 1.35 (0.77–2.37) | 0.30 | 1.37 (0.77–2.44) | 0.28 | 0.92 (0.42–2.01) | 0.83 |
| CPI ≥ code 3 | 1.83 (1.03–3.25) | 1.84 (1.04–3.27) | 2.01 (0.95–4.28) | 0.07 | ||
| APOE ε4 allele carrier | 0.84 (0.40–1.75) | 0.64 | 0.87 (0.48–1.58) | 0.66 | 0.89 (0.33–2.38) | 0.81 |
| Collagen binding activity ≥10% | 9.11 (4.94–16.8) | 9.68 (5.17–18.1) | 14.3 (6.53–31.1) |
†Odds ratio (OR), 95% confidence interval (CI), Bold values mean statistical significance at p < 0.05.
Model 1: adjusted by age and sex.
Model 2: adjusted by age, sex, BMI, hypertension, hyperlipidemia, diabetes mellitus, history of stroke and cardiovascular disease, alcohol consumption, cigarette smoking, antiplatelet therapy, anticoagulant therapy, education, baPWV, hs-CRP, dental caries, CPI, APOE ε4 allele carrier and collagen binding activity.
BMI; Body mass index, CPI; Community Periodontal Index.
Comparison of characteristics between cnm-positive Streptococcus mutans (+) group and (−) group and background of collagen binding activity between the (+) group and the (−) group.
| Variable | Collagen binding activity ≥10% | |||
|---|---|---|---|---|
| − (n = 188) | + (n = 91) | − (n = 208) | + (n = 71) | |
| n (%) | n (%) | n (%) | n (%) | |
| Clinical characteristics | ||||
| Age (years) ± SD | 70.1 ± 6.1 | 68.9 ± 5.9 | 70.0 ± 6.1 | 69.1 ± 6.0 |
| Age (range) | 54–89 | 60–87 | 54–89 | 60–87 |
| Sex (Male) | 132 (70) | 57 (63) | 144 (69) | 45 (63) |
| BMI (kg/m2) ± SD | 22.6 ± 2.5 | 23.0 ± 3.6 | 22.6 ± 2.7 | 23.0 ± 3.6 |
| Hypertension | 94 (50) | 51 (56) | 105 (51) | 40 (56) |
| Hyperlipidemia | 108 (57) | 57 (63) | 123 (59) | 42 (59) |
| Diabetes mellitus | 25 (13) | 10 (11) | 28 (14) | 7 (9.9) |
| History of stroke | 4 (2.1) | 1 (1.1) | 4 (1.9) | 1 (1.4) |
| History of cardiovascular disease | 7 (3.7) | 7 (7.7) | 9 (4.3) | 5 (7.0) |
| Antiplatelet therapy | 17 (9.0) | 12 (13) | 21 (10) | 8 (11) |
| Anticoagulant therapy | 8 (4.3) | 3 (3.3) | 9 (4.3) | 2 (2.8) |
| Drinking | 129 (69) | 52 (57) | 123 (59) | 42 (59) |
| Smoking | 24 (13) | 7 (7.7) | 12 (5.8) | 4 (5.6) |
| Education ≤12 yearsa | 102 (55) | 48 (55) | 112 (55) | 38 (54) |
| baPWV (m/s) ± SD | 1728 ± 292.5 | 1755 ± 329.5 | 1728 ± 298.3 | 1761 ± 323.6 |
| hs-CRP ≥ 0.1 mg/dL | 49 (26) | 28 (31) | 52 (25) | 25 (35) |
| Dental check-up findings | ||||
| Number of remaining teeth ± SD | 22.7 ± 7.5 | 22.8 ± 7.4 | 22.7 ± 7.5 | 22.8 ± 7.4 |
| Dental caries+ | 52 (28) | 34 (37) | 52 (25) | 34 (48)** |
| CPI ≥ code 3 | 48 (26) | 29 (32) | 56 (27) | 21 (30) |
| Laboratory evaluations | ||||
| APOE ε4 allele carrierb | 40 (22) | 18 (20) | 44 (22) | 14 (20) |
| Collagen binding activity ≥10% | — | 71 (78) | — | — |
| Brain MRI findings | ||||
| CMBs | 19 (10) | 54 (59)** | 30 (14) | 43 (61)** |
| Distribution of CMBs | ||||
| Deep (%) | 6 (32) | 38 (70)** | 15 (50) | 29 (67)** |
| Lobar (%) | 11 (58) | 9 (17) | 13 (43) | 7 (16) |
| Mixed (%) | 2 (11) | 7 (13) | 2 (6.7) | 7 (16) |
| PVH ≥ grade 2 | 24 (13) | 11 (12) | 26 (13) | 9 (13) |
| DWMH ≥ grade 2 | 51 (27) | 26 (29) | 56 (27) | 21 (30) |
| Cognitive functional evaluations | ||||
| MMSE (score) ± SD | 28.4 ± 2.2 | 28.3 ± 2.0 | 28.3 ± 2.3 | 28.5 ± 1.8 |
| Letter fluency tasks | ||||
| “Ta” (score) ± SD | 8.4 ± 3.6 | 8.0 ± 2.8 | 8.5 ± 3.5 | 7.6 ± 2.8** |
| “Ka” (score) ± SD | 10.1 ± 3.4 | 9.2 ± 3.2* | 10.1 ± 3.4 | 8.9 ± 3.3** |
*T-tests p < 0.05 and Chi-square tests p < 0.05, **T-tests p < 0.01 and Chi-square tests p < 0.01. aData are missing for education (n = 4).
bData are missing for APOE genotype (n = 7). BMI; Body mass index, CPI; Community Periodontal Index, CMBs; Cerebral microbleeds.
PVH; Periventricular Hyperintensity, DWMH; Deep White Matter Hyperintensity, MMSE; Mini-Mental State Examination.